All News
As the Omicron variant of the SARS-CoV-2 virus sweeps much of the globe, scientists are digging into why this particular mutation is spreading even more rapidly than its predecessors.
Nodexus and Aramis Biosciences will use their funds to expand their company’s pipeline and build their commercialization capabilities.
Researchers have published a study describing how chemotherapy and a drug used to treat cardiac failure is able to regress tumor growth of patients with triple negative breast cancer.
Biopharmaceutical companies across the world are fighting an increasingly important battle against COVID-19: the struggle to treat the disease.
The FDA said Orencia is the first drug approved as prophylaxis for aGVHD prevention that included real-world evidence as one component of clinical efficacy.
Eli Lilly and Company’s projections for next year exceed Wall Street projections for the company, predicting 2022 revenue of $27.8 billion to $28.3 billion.
Biopharma and life sciences companies from across the globe provide updates on their businesses and pipelines.
Shares of BeiGene have fallen 16% in China in part due to concerns over potential U.S. sanctions against Chinese biotech companies.
Sanofi and GlaxoSmithKline reported that their potential COVID-19 booster shot delivered good immune response in its preliminary clinical trials.
It’s no secret that employers ask tricky interview questions. But what do you do if you find yourself fumbling for words to answer these tricky questions?
Generation Bio’s stock plummeted 54% to $6.35 yesterday after it reported in an SEC filing that its hemophilia A therapy data in mice couldn’t be duplicated in non-human primate studies.
The FDA approved the latest indication for Rinvoq (upadacitinib) based on data from two Phase III studies, SELECT-PsA 1 and SELECT-PsA 2.
Although it’s not yet clear how dangerous the Omicron variant of COVID-19 actually is, it clearly is very infectious and rates are rising in the U.S. and around the world.
These results set Lilly up well to submit a Biologics License Application (BLA) in the first half of 2022.
The latest warning letter asks Medtronic to update its systems and procedures in order to deliver safe and high-quality devices to consumers.
Mythic Therapeutics has roared out of the gate with a $103 million Series B financing round that will support “safer and smarter” next generation of antibody-drug conjugates (ADCs).
Many big companies, including Amgen, Moderna, Roche and Novartis, had already decided not to attend in-person and the sentiment was leaning that way.
The FDA’s approval of Xeljanz is based on Pfizer’s Phase III multicenter, double-blind, placebo-controlled study. Here are more details about the study.
During a season of giving, investors were extra generous to these biotech companies this week.
A member of BioSpace’s Class of 2021, CODA aims to modify neuronal cell populations using gene therapy to express a tunable ligand-gated ion channel.